ClinicalTrials.gg
CompletedNCT00910637Updated Apr 8, 2021

Study Investigating the Efficacy and Safety of a Contraceptive Patch for 13 Cycles

A Phase 3 interventional study of Gestodene/EE Patch (BAY86-5016) in Contraception, sponsored by Bayer. Completed at 63 sites in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-04-08.

Sponsored by Bayer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,502
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

This study is examining a birth control patch for 13 cycles (1 year).

02

Conditions studied

  • Contraception

Keywords

  • Pregnancy prevention
  • Female contraception
  • Patch
03

In context

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Requiring
  • Normal cervical smear
  • Maximum age for smokers is 35
  • History of regular cyclic menstrual periods

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation
  • Significant skin reaction to transdermal preparations or sensitivity to surgical / medical tape
  • Any disease that may worsen under hormonal treatment (cardiovascular, liver, metabolic)
  • Use of other methods than study medication
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
1,502 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Gestodene/EE Patch (BAY86-5016)

Interventions

  • DrugGestodene/EE Patch (BAY86-5016)

    Drug pages: Gestodene · Ethinyl Estradiol

    55 mg ethinyl estradiol \& 2.1 mg gestodene, 21 days for 13 cycles

06

What researchers measure

Primary outcomes

  1. Occurrence of pregnancy (yes/no) while on treatment

    Time frame: 13 treatment cycles each consisting of 28 days and follow-up period of 14 days

Secondary outcomes

  1. Vital signs

    Time frame: 13 treatment cycles each consisting of 28 days

  2. Physical and gynecological examinations

    Time frame: 13 treatment cycles each consisting of 28 days

  3. Laboratory assessments

    Time frame: 13 treatment cycles each consisting of 28 days

  4. Adverse events (AE monitoring)

    Time frame: 13 treatment cycles each consisting of 28 days

07

Study locations

63 sites
  • Birmingham, Alabama 35235, United States
  • Glendale, Arizona 85304, United States
  • Precision Trials
    Phoenix, Arizona 85032, United States
  • Visions Clinical Research - Tucson
    Tucson, Arizona 85712, United States
  • Carmichael, California 95608, United States
  • Pacific Palisades, California 90272, United States
  • Paramount, California 90723, United States
  • Genesis Center for Clinical Research
    San Diego, California 92103, United States
  • San Diego, California 92108, United States
  • San Diego, California 92123, United States
  • Santa Ana, California 92705, United States
  • Torrance, California 90502, United States
  • Denver, Colorado 80218, United States
  • Littleton, Colorado 80122, United States
  • New London, Connecticut 06320, United States
  • Visions Clinical Research
    Boynton Beach, Florida 33472-2952, United States
  • Jacksonville, Florida 32207, United States
  • Miami, Florida 33186, United States
  • Pembroke Pines, Florida 33024, United States
  • Meridien Research
    Saint Petersburg, Florida 33709, United States
  • Atlanta, Georgia 30328, United States
  • Decatur, Georgia 30034, United States
  • Roswell, Georgia 30075, United States
  • Research Associates
    Boise, Idaho 83702, United States
  • Rosemark Women Care Specialist
    Idaho Falls, Idaho 83404, United States
  • Chicago, Illinois 60612, United States
  • Newburgh, Indiana 47630, United States
  • South Bend, Indiana 46601, United States
  • Marrero, Louisiana 70072, United States
  • Boston, Massachusetts 02118, United States
  • Chaska, Minnesota 55318, United States
  • Lincoln, Nebraska 68510, United States
  • Las Vegas, Nevada 89030, United States
  • Las Vegas, Nevada 89106, United States
  • Office of Dr. R. Garn Mabey, MD
    Las Vegas, Nevada 89128, United States
  • Lawrenceville, New Jersey 08648, United States
  • Moorestown, New Jersey 08057, United States
  • Albuquerque, New Mexico 87102, United States
  • New York, New York 10032, United States
  • New Bern, North Carolina 28562, United States
  • Winston-Salem, North Carolina 27103, United States
  • Cincinnati, Ohio 45267-0457, United States
  • Cleveland, Ohio 44122, United States
  • Columbus, Ohio 43213, United States
  • York Clinical Consulting
    Oklahoma City, Oklahoma 73120, United States
  • Eugene, Oregon 97401, United States
  • Portland, Oregon 97239-3011, United States
  • Philadelphia, Pennsylvania 19114, United States
  • Pittsburgh, Pennsylvania 15213, United States
  • Warwick, Rhode Island 02886, United States
  • Columbia, South Carolina 29201, United States
  • Mount Pleasant, South Carolina 29464, United States
  • Chattanooga, Tennessee 37404, United States
  • Knoxville, Tennessee 37920, United States
  • Women's Care Center, PLC
    Memphis, Tennessee 38119, United States
  • Nashville, Tennessee 37203, United States
  • Nashville, Tennessee 37205, United States
  • Corpus Christi, Texas 78414, United States
  • Practice Research Organization
    Dallas, Texas 75230, United States
  • Advances in Health, inc.
    Houston, Texas 77030, United States
  • The Woman's Hospital of Texas
    Houston, Texas 77054, United States
  • Norfolk, Virginia 23507, United States
  • Women's Clinical Research Center
    Seattle, Washington 98105, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2009 to primary completion in Dec 2010, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2009
First posted
Jun 1, 2009
StartActual
May 1, 2009
Primary completionActual
Dec 13, 2010
CompletionActual
Dec 13, 2010
Last update
Apr 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00910637
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jun 1, 2009
Start date
May 1, 2009
Primary completion
Dec 13, 2010
Completion
Dec 13, 2010
Last update
Apr 8, 2021

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gestodene · Ethinyl Estradiol

Start the discussion